Clinical trials: Antiviral Drug Adverse Reaction
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.
- Trial name
- TACEHBV (NCT01102335)
- Testing
- Transcatheter arterial chemoembolization (TACE), Telbivudine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Hepatitis B, Antiviral Drug Adverse Reaction
Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance
To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in CHB patients with antiviral resistance, as determined by the proportion of…
- Trial name
- NCT03566030
- Testing
- Tenofovir disoproxil fumarate 300mg, Tenofovir Alafenamide 25 mg
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of
Possible Differences in HCC Course Depending on DAA Treatment
BACKGROUND It is estimated that around 71 milion people live with chronic hepatitis C virus (HCV) infection. This may lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC).
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of, Drug Effect, Drug Side Effect
- Trial name
- NCT05376943
- Testing
- Direct Acting Antivirals
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Hepatitis C, Cirrhosis
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of…
- Conditions
- Hepatitis C, Cirrhosis, Antiviral Drug Adverse Reaction
- Trial name
- NCT03775798
- Testing
- Direct antiviral agents for hepatitis C
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Austral University, Argentina
Chronic Hepatitis C, Medication Reaction
The Efficacy of Vosevi in Treating DAA-experienced Patients
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015.
- Trial name
- NCT06180590
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
HIV/AIDS, Antiviral Toxicity
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Increased comorbidities such as cardiovascular disease (CVD), are emerging problems in HIV infection but the mechanisms are unclear.
- Conditions
- HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
- Trial name
- UCLACAREMITO (NCT03251144)
- Testing
- Switch to E/C/FTC/TAF daily
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Drug-Induced Liver Injury
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC
- Trial name
- NCT03602703
- Testing
- Flow cytometry and Western Blot analysis
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Assiut University
Antiviral Drug Adverse Reaction
Effect Of DAAs For Treatment Of HCV On Normal Kidney
The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.
- Trial name
- NCT03296930
- Testing
- Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis C, Chronic
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C
The investigators will assess whether patients with the Hepatitis C virus (HCV) who are prescribed direct-acting antiviral (DAA) medications experience higher rates of adverse events than patients with HCV who are untreated.
- Trial name
- NCT03423641
- Testing
- Direct Acting Antivirals
- Volunteers
- 33,808 people
- Sponsor
- Kaiser Permanente
HIV-1-infection, Antiviral Drug Adverse Reaction
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir…
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities
- Trial name
- NCT04340388
- Testing
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Augusta University